Telisotuzumab vedotin
Based on 3 publication(s) in Google Scholar
Telisotuzumab vedotin (ABBV-399) (Teliso-V) is an anti-c-Met antibody-drug conjugate. Telisotuzumab vedotin consists of an anti-c-Met monoclonal antibody Telisotuzumab (ABT-700) (HY-P99391) and Monomethyl Auristatin E (HY-15162). Telisotuzumab vedotin exerts antitumor activity with acceptable toxicity in vivo. Telisotuzumab vedotin can be used for non-small cell lung cancer (NSCLC) research.
For research use only. We do not sell to patients.
- CAS No.: 1714088-51-3
- Molecular Weight:145000 (average)
-
Storage:
-80°C, protect from light
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Protocols
- Purity & Documentation
- References
-
Help & FAQs
-
HY-152963
Tisotumab vedotinAntibody-Drug Conjugate -
HY-138298A
Trastuzumab deruxtecanHER2 ADC -
HY-P9985
Disitamab vedotinHER2-Directed ADC -
HY-141598
Datopotamab deruxtecan (solution)TROP2-Targeted ADC -
HY-P99813
Patritumab deruxtecanHER3-Directed ADC -
HY-138298
Trastuzumab deruxtecan (solution)HER2 ADC -
HY-P99107A
Brentuximab vedotin (solution)ADC -
HY-132253
Polatuzumab vedotinMicrotubule Inhibitor -
HY-132254
Sacituzumab govitecanTrop-2 ADC -
HY-P9921
Trastuzumab emtansineAntibody-drug Conjugate -
HY-132258A
Mirvetuximab soravtansine (solution)ADC -
HY-P3239
Belantamab mafodotinAnti-BCMA ADC
Publications Citing Use of MedChemExpress (MCE) Telisotuzumab vedotin
More
Customer Validation & Images
-
In Vivo Efficacy Study
-
In Vivo Imaging
-
In Vivo Efficacy Study
Biological Activity
Description
In Vitro
Telisotuzumab vedotin (ABBV-399) demonstrates potent cytotoxicity that is dependent on a threshold level of target expression and is not reliant on inhibiting MET signaling in tumor cell lines with high c-Met expression or MET amplification[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
In Vivo
Clinical Trial
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
CAS No. 1714088-51-3
-
Appearance Liquid
-
Molecular Weight 145000 (average)
-
Color Colorless to light yellow
-
SMILES
[Telisotuzumab vedotin]
-
Synonyms
ABBV-399
-
Shipping
Shipping with dry ice.
-
Storage
-80°C, protect from light
Publications (3)
-
Journal Impact Factor
-
Most Recent
-
Cell Rep Med
A bispecific nanobody-drug conjugate targeting TROP2 and c-Met for low-concentration, single-dose treatment of pancreatic cancer. [Abstract]2026 Apr 21;7(4):102688. PMID: 41856115
Telisotuzumab vedotin purchased from MedChemExpress. Usage Cited in: Cell Rep Med. 2026 Apr 21;7(4):102688. [Abstract]
Comparison of tumor suppression between B6ADC and the combination of “marketed TROP2ADC (SG) and marketed c-MetADC (Telisotuzumab vedotin, 10 nmol/kg)” in SPC-A1 tumor-bearing mice (initial tumor volume: 600 mm3) (n = 5∼7/group).
Telisotuzumab vedotin purchased from MedChemExpress. Usage Cited in: Cell Rep Med. 2026 Apr 21;7(4):102688. [Abstract]
Bioluminescence imaging of mice with orthotopic pancreatic tumors treated with B6ADC or the combination of "SG and Telisotuzumab vedotin (10 nmol/kg)" for 28 days (n = 4/group).
Telisotuzumab vedotin purchased from MedChemExpress. Usage Cited in: Cell Rep Med. 2026 Apr 21;7(4):102688. [Abstract]
Survival curves of mice treated with B6ADC or SG+Telisotuzumab vedotin (10 nmol/kg). Survival analysis was performed using the Kaplan-Meier method, and statistical significance was determined by the log rank (Mantel-Cox) test.
-
Mol Cancer Ther
HRA00129-C004, a Novel c-Met Antibody-Drug Conjugate (ADC), Exerts Encouraging Anti-Tumor Activities and Favorable Safety Profiles. [Abstract]2025 Oct 30. PMID: 41166693 -
Protocols
-
Subcutaneous Cell-Line-Derived Xenograft
Subcutaneous cell-line-derived xenograft (CDX) models are established by implanting cultured human cancer cell lines into immunodeficient mice, where the injected cells form localized tumors that can be monitored in vivo as a measure of tumorigenic potential, growth kinetics, and treatment response. These models are widely used in oncology research because they allow reproducible tumor formation and enable comparative assessment of tumor growth between different cell lines or genetic manipulations in a controlled in vivo microenvironment. Subcutaneous implantation of cancer cells in immunodeficient mice is a standard approach for evaluating tumor growth behavior and therapeutic response across multiple cancer types, including prostate, esophageal, pancreatic, and colon cancer models.
Purity & Documentation
-
Data Sheet (268 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Handling Instructions (2659 KB)
References
[1]. Strickler JH, et al. First-in-Human Phase I, Dose-Escalation and -Expansion Study of Telisotuzumab Vedotin, an Antibody-Drug Conjugate Targeting c-Met, in Patients With Advanced Solid Tumors. J Clin Oncol. 2018 Nov 20;36(33):3298-3306. [Content Brief]
[2]. Camidge D R, et al. Phase Ib study of telisotuzumab vedotin in combination with erlotinib in patients with c-met protein–expressing non–small-cell lung cancer. Journal of Clinical Oncology, 2023, 41(5): 1105-1115. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Telisotuzumab vedotin Related Classifications
HY-141601 Related Classifications
Powered by Bioz